<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>32172</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1472-6904-1-1</infon><infon key="article-id_pmc">32172</infon><infon key="article-id_pmid">11228592</infon><infon key="article-id_publisher-id">1472-6904-1-1</infon><infon key="fpage">1</infon><infon key="journal-title">BMC Clinical Pharmacology</infon><infon key="lpage">1</infon><infon key="name_0">surname:de Abajo;given-names:Francisco J</infon><infon key="name_1">surname:García Rodríguez;given-names:Luis A</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">1</infon><infon key="year">2001</infon><offset>0</offset><text>Risk of upper gastrointestinal bleeding and perforation associated  with low-dose aspirin as plain and enteric-coated formulations</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>131</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>142</offset><text>The use of low-dose aspirin has been reported to be associated with an  increased risk of upper gastrointestinal complications (UGIC). The coating of  aspirin has been proposed as an approach to reduce such a risk. To test this  hypothesis, we carried out a population based case-control study.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>437</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>445</offset><text>We identified incident cases of UGIC (bleeding or perforation) aged 40 to 79  years between April 1993 to October 1998 registered in the General Practice  Research Database. Controls were selected randomly from the source population.  Adjusted estimates of relative risk (RR) associated with current use of aspirin  as compared to non use were computed using unconditional logistic  regression.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>840</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>848</offset><text>We identified 2,105 cases of UGIC and selected 11,500 controls. Among them,  287 (13.6%) cases and 837 (7.3%) controls were exposed to aspirin, resulting in  an adjusted RR of 2.0 (1.7-2.3). No clear dose-effect was found within the  range of 75-300 mg. The RR associated with enteric-coated formulations (2.3,  1.6-3.2) was similar to the one of plain aspirin (1.9, 1.6-2.3), and no  difference was observed depending on the site. The first two months of  treatment was the period of greater risk (RR= 4.5, 2.9-7.1). The concomitant  use of aspirin with high-dose NSAIDs greatly increased the risk of UGIC (13.3,  8.5-20.9) while no interaction was apparent with low-medium doses (2.2,  1.0-4.6).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1546</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1558</offset><text>Low-dose aspirin increases by twofold the risk of UGIC in the general  population and its coating does not modify the effect. Concomitant use of  low-dose aspirin and NSAIDs at high doses put patients at a specially high risk  of UGIC.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1794</offset><text>Background</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1805</offset><text>Upper gastrointestinal complications (UGIC) are the major risk associated  with aspirin use. As with non-aspirin non-steroidal  antiinflammatory drugs (NSAIDs), dose appears to be a major determinant, but  even with low (300/325 mg) or very low doses (75 mg) a residual amount of risk  seems to persist.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2109</offset><text>It has been postulated that enteric-coated formulations of aspirin, designed  to resist the disintegration in acid environment and pass by the stomach  without dissolution, may have an impact in reducing the risk. The idea behind this strategy is grounded on the belief that gastric  damage caused by aspirin is mainly due to a local effect. Results from several endoscopic studies carried out in healthy  volunteers supported this hypothesis showing that enteric-coated aspirin caused  less gastric erosion and microbleeding than regular formulations. However, it  is known that these lesions are not good predictors of major upper  gastrointestinal complications. From an epidemiological point of view the  question is a matter of controversy as well. Two case-control studies have  reported data on the effect of enteric-coated preparations on upper  gastrointestinal bleeding, yielding to apparently opposite results. Weil et al   concluded that &quot;enteric-coated aspirin ... may be  free of risk&quot; after estimating an odds ratio of 1.6 but with a wide 95%  confidence interval (0.5-4.9). On the other hand, Kelly et al found a risk of 2.6 (95% confidence interval, 1.4-5.3) which was  essentially similar to the one estimated for plain aspirin when the effect of  dose was taken into account.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3404</offset><text>In order to shed some light onto this issue and to estimate the specific  aspirin-related risk of upper gastrointestinal bleeding and perforation, its  relation with dose and duration of treatment, as well as the potential  interaction between aspirin and other drugs (particularly NSAIDs), we used data  from a case-control study designed to estimate risks of UGIC associated with  drugs and other factors.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3812</offset><text>Subjects and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3833</offset><text>A case-control study was carried out using data from the UK-based General  Practice Research Database. This database has been described extensively  elsewhere. Briefly, it contains details of  patients' demographics, medical diagnosis, referrals to consultants and  hospitals, and prescriptions. The accuracy and completeness of these data have  been validated in previous studies.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4215</offset><text>Case definition and ascertainment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4249</offset><text>The source population was encompassed by patients aged 40 to 79 years  between April 1993 and October 1998, with at least 2 years' enrollment with  their general practitioner. Patients with cancer, oesophageal varices,  Mallory-Weiss disease, alcoholism, liver disease, or coagulopathies were  excluded. We identified incident cases of upper gastrointestinal bleeding or  perforation, and reviewed their computerised profiles. The date of first  diagnosis was used as the index date. Patients with any of the exclusion  criteria mentioned above in the 2 months after index date, those discharged  from hospital in the two previous weeks, and subjects with the source of the  bleed/perforation in the oesophagus or lower gastrointestinal tract were not  retained as cases. A patient was considered a case of UGIC when no exclusion  criterion was found, and the specific site of bleed/perforation was located in  the stomach or duodenum or the clinical diagnosis was peptic ulcer. Only  patients referred to a specialist or admitted to hospital were retained as  cases. To confirm the validity of our computer-based case ascertainment, we  requested from the general practitioners a copy of the paper-based records of  100 randomly sampled patients. We received records for 99 patients of which 98  were confirmed as cases. We therefore decided to study all patients classified  as cases on the basis of the review of computerised information. Patients with a fatal outcome within a month of the  beginning of the episode were considered as fatal cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5801</offset><text>Control selection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5819</offset><text>All patients from the source population were assigned a random date during  the study period. If such random date fell within his/her observation period,  that patient was considered eligible as control. From this population we  randomly selected 11,500 patients frequency-matched with cases for age  (interval of 1 year), sex and calendar year. We applied to controls the same  exclusion criteria used for cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6233</offset><text>Exposure definition</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6253</offset><text>We defined patients as &quot;current users&quot; when the supply of a prescription for  aspirin lasted until the index date or ended within the period of 30 days  before index date, &quot;recent users&quot; when the supply ended between 31 to 180 days  before the index date, &quot;past users&quot; if the supply ended more than 180 days  before and &quot;non-users&quot; if no prescription was ever recorded before the index  date. Among current and recent use categories we also explored narrower  exposure windows. Among current users, we studied the effect of dose, treatment  duration and formulation of aspirin. For the estimation of daily dose two  different approaches were followed: 1) the dose instructed by the general  practitioner and 2) the average dose calculated by dividing the number of  tablets supplied (provided that at least three prescriptions were written  before index date) over the treatment period. Although a wide range of  different strengths of low-dose aspirin are available in the U.K., the most  widely used by general practitioners are 75 mg and 300 mg. A number of  physicians prescribed a 300 mg tablet to be taken in alternate days; from a  risk perspective, we considered such patients closer to the 300 mg group and  were included in this category. Duration of treatment was calculated by adding  up the time corresponding to consecutive prescriptions of aspirin before the  index date, considering two prescriptions as consecutive when the interval  between the end of supply of one prescription and the start of the next one was  less than 120 days (this interval was meant to make a clear separation between  those patients actually starting a new treatment course with aspirin from those  having a poor compliance). Further, among current users we distinguished  between those patients whose aspirin treatment course was the first ever  recorded in the GPRD over the study period, and those with a previous (or  distant) use. The indication of aspirin was studied among current users in two  random samples of 100 subjects each among cases and controls. All manual review  was done blinded to the status of each patient (case or control).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8396</offset><text>We also evaluated the exposure to other drugs such as non-aspirin NSAIDs,  paracetamol, steroids, anticoagulants, selective serotonin reuptake inhibitors  and antiulcer drugs (antacids, H2-blockers and omeprazol). Among current users  of NSAIDs, we distinguished between low-medium and high daily doses using the  cut-off limits described in previous studies.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8756</offset><text>Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8765</offset><text>We used unconditional logistic regression to compute adjusted estimates of  relative risk and 95% confidence intervals (95% CI) for current use of aspirin  as compared to non-use. Two different outcomes were studied: upper  gastrointestinal bleeding (UGIB) and perforation. The location of the lesion  was considered in the analysis when number of cases allowed for that. Also, we  examined separately fatal cases. The following covariates were studied as  potential confounders: history of upper gastrointestinal disorder (dyspepsia,  peptic ulcer, upper gastrointestinal bleeding/perforation), smoking status  (information available for 84% of study population), alcohol consumption  (information available for 58% of study population), and current use of drugs  related with an increased risk of upper gastrointestinal complications:  non-aspirin NSAIDs, anticoagulants, corticosteroids  , high-dose (&gt; 2 grams) paracetamol and selective serotonin reuptake inhibitors. The matching factors were included in the model as well.  We studied the interaction between aspirin and other drugs by forming one  single term in the model for the joint effect. The relative excess risk due to  interaction (RERI) was used as a measure of interaction and was calculated as:  Relative risk (current joint use of &quot;a&quot; and &quot;b&quot;)-relative risk (current use of  &quot;a&quot; only)- relative risk (current use of &quot;b&quot; only) + 1, being &quot;a&quot; and &quot;b&quot; the  factors whose interaction is being studied.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10233</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10241</offset><text>We identified 1,833 cases of upper gastrointestinal bleeding and 272 cases  of perforation. Cases and controls did not differ by age group and sex (table  1). Among bleeding cases, the lesion was located at the  stomach in 764 (42%) and the duodenum in 811 (44%), remaining unspecified in  258 (14%); 4.1% of bleeding cases were fatal. Among perforation cases, 36 (13%)  were located in the stomach and 236 (87%) in the duodenum with a case-fatality  rate of 21.0 %. Two hundred eighty seven cases (13.6%) of upper  gastrointestinal bleeding (n= 248; 13.5%) or perforation (n= 39; 14.3%) were  current users of aspirin, as compared to 837 current users among controls  (7.3%) yielding to an adjusted RR of 2.0 (95% CI: 1.7-2.3) for all cases (table  2). No material difference was found when upper  gastrointestinal bleeding (2.0, 1.7-2.4) and perforation (1.7, 1.2-2.6) were  considered as separate outcomes, or when location was taken into account  (gastric 2.0, 1.6-2.5; duodenal 1.7, 1.4-2.1). The risk was essentially the  same either for fatal (1.8, 1.1-2.9) or nonfatal (2.0, 1.7-2.4) cases. No  modification of the relative risk estimates was observed by sex (males, 2.0  (1.6-2.4); females, 2.0 (1.5-2.6). The relative risks by age group were as  follows: 40-59 years, 2.4 (1.3-4.4); 60-69 years, 2.3 (1.8-3.1); 70-79 years,  1.8 (1.4-2.2).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11591</offset><text>Distribution of study population by sex and age group</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Gender&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;Male&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1,327 (63.0 
%)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;7,167 (62.3 %)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Age group&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;40-59&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;667 (31.7 
%)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3,766 (32.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;60-69&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;627 (29.8 
%)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3,392 (29.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;70-79&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;811 (38.5 
%)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4,342 (37.8 %)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11645</offset><text>	Cases		 	Controls	 		(N=2,105)		 	(N=11,500)	 	Gender			 	 Male	1,327 (63.0 	 	%)	7,167 (62.3 %)	 	Age group			 	 40-59	667 (31.7 	 	%)	3,766 (32.8%)	 	 60-69	627 (29.8 	 	%)	3,392 (29.5%)	 	 70-79	811 (38.5 	 	%)	4,342 (37.8 %)	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11886</offset><text>Risk of UGIB and perforation associated with aspirin use</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Non-use&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1,696&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10,157&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1 (reference)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Current use (1-30)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;287&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;837&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.7-2.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;Use within 1-7&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;259&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;771&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;2.0 (1.7-2.3)&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;days time window&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;Use within 8-30&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;28&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;66&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;2.3 (1.4-3.7)&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;days time window&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Recent use (31-180)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;37&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;123&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.5 (1.0-2.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;Use within 31-60&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;14&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;45&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;1.7 (0.9-3.3)&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;days time window&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;Use within 61-180&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;23&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;78&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;italic&gt;1.5 (0.9-2.5)&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;&lt;italic&gt;days time window&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Past use (&amp;gt;180)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;85&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;383&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.1 (0.8-1.4)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11943</offset><text>	All cases		 	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Non-use	1,696	10,157	1 (reference)	 	Current use (1-30)	287	837	2.0 (1.7-2.3)	 	 Use within 1-7	259	771	2.0 (1.7-2.3)	 	 days time window				 	 Use within 8-30	28	66	2.3 (1.4-3.7)	 	 days time window				 	Recent use (31-180)	37	123	1.5 (1.0-2.3)	 	 Use within 31-60	14	45	1.7 (0.9-3.3)	 	 days time window				 	 Use within 61-180	23	78	1.5 (0.9-2.5)	 	 days time window				 	Past use (&gt;180)	85	383	1.1 (0.8-1.4)	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>12447</offset><text>* Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12636</offset><text>The indications for aspirin among a random sample of 100 cases were  secondary prevention of coronary heart disease (47), secondary prevention of  cerebrovascular ischaemic events (36), peripheral vascular disease (5), other  cardiovascular disease (2), and analgesia (2). For the remainder (8) the  indication was not unequivocally identified from the patient profiles. The  distribution of indications in a random sample of 100 controls was 50, 30, 5,  3, 2 and 10, respectively.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13118</offset><text>Seventy-five mg was the daily dose most frequently prescribed (48%) in  controls, followed by 150 mg (27%), 300/325 mg (19%), and more than 325 mg  (6%). No dose-effect relation was observed with aspirin within the 75-300 mg  range according to the instructions written by the general practitioner (table  3). This remained true when the analysis was restricted  to a specific lesion (either bleeding or perforation) or to a specific location  (either gastric or duodenal) (see additional material: Appendix 1). Results did  not materially change when only patients without any antecedents of  gastrointestinal disorders (including dyspepsia) were considered (see  additional material: Appendix 2), or when we controlled for use of antiulcer  drugs. For 149 patients (45 (16%) cases and 104 (12%) controls) among current  users the average daily dose estimated through the number of tablets supplied  exceeded the cut-off values established to separate different dose categories  (112, 225 and 400 mg). The replacement of the &quot;instructed dose&quot; by the average  dose did not make a significant change (table 3). Nor did  the restriction of the analysis to patients with consistent data for both  methods of aspirin dose assessment.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>14348</offset><text>Relation between aspirin dose and risk of UGIB and perforation 
among current users as compared to non-use</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Daily dose as instructed&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 75 mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;141&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;420&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.6-2.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 150 mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;84&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;245&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.5-2.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 300 mg$&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;54&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;163&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.4-2.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 600 + mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.0 (1.4-11.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Average daily dose +&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &amp;lt;50 mg (irregular use)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;
4&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;29&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.7 (0.2-2.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 51-111&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;135&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;383&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.1 (1.7-2.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 112-225&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;91&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;258&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.5-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 226-400&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;48&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;151&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.4-2.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &amp;gt; 400&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;16&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3.1 (1.3-7.5)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>14455</offset><text>	All cases		 	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Daily dose as instructed				 	 75 mg	141	420	1.9 (1.6-2.4)	 	 150 mg	84	245	2.0 (1.5-2.6)	 	 300 mg$	54	163	2.0 (1.4-2.8)	 	 600 + mg	8	9	4.0 (1.4-11.5)	 	Average daily dose +				 	 &lt;50 mg (irregular use)		 	4	29	0.7 (0.2-2.0)	 	 51-111	135	383	2.1 (1.7-2.6)	 	 112-225	91	258	1.9 (1.5-2.5)	 	 226-400	48	151	2.0 (1.4-2.9)	 	 &gt; 400	9	16	3.1 (1.3-7.5)	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>14900</offset><text>* Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment 
for use of antiulcer drugs (antacids, H2-blockers and omeprazol) did not change 
the estimates. $ Five cases and three controls taking 300 mg in alternate days 
were included in this category. Assigning those patients to the 150-mg category 
hardly modified the results. + Calculated by dividing the number of tablets 
supplied over the treatment period. For 161 patients (51 (18%) cases and 110 
(13%) controls) less than 3 prescriptions of aspirin were written, therefore 
the instructed dose was still considered in these patients.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15647</offset><text>Enteric-coated aspirin was associated with a risk of UGIC (RR of 2.3,  1.6-3.2) similar to the one of plain aspirin (1.9, 1.6-2.3). Estimates hardly  changed when analysing separately bleeding and perforation, or gastric and  duodenal sites (table 4). As enteric-coated aspirin could  have been prescribed preferentially for those patients at greater risk of  gastrointestinal damage, we performed a sub-analysis including only individuals  without any antecedent of upper gastrointestinal disorder: the relative risk  estimate for enteric-coated aspirin was 2.7 (1.7-4.2) and the one for plain  aspirin was 2.2 (1.8-2.8). The results did not change when additional  adjustment for antiulcer drugs use was performed. Estimates of risk associated  with aspirin formulation and stratified by dose are shown in table 5. We observed a dose-response starting at 300 mg with plain  aspirin but could not find a similar pattern with enteric-coated.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>16589</offset><text>Risk of UGIB and perforation associated with aspirin use according 
to location, type of lesion and aspirin formulation</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot; colspan=&quot;3&quot;&gt;&lt;bold&gt;Adjusted&lt;sup&gt;*&lt;/sup&gt;
 RR (95% CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;UGIB&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Perforation&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All sites&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Plain&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.6-2.3)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.6-2.4)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.6 (1.1-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Coated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.3 (1.6-3.2)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.2 (1.5-3.2)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.4 (1.1-5.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Gastric&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Plain&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.5-2.5)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.6-2.6)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;- $&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Coated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.2 (1.4-3.6)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.3 (1.4-3.8)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Duodenal&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Plain&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.6 (1.3-2.1)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.5 (1.2-2.0)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.8 (1.1-2.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Coated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.2 (1.4-3.4)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.1-3.2)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.9&lt;sup&gt;#&lt;/sup&gt; 
(1.4-6.1)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16709</offset><text>		Adjusted*	 	 RR (95% CI)	 				 			All cases	UGIB	Perforation	 	All sites	Plain	1.9 (1.6-2.3)	2.0 (1.6-2.4)	1.6 (1.1-2.5)	 		Coated	2.3 (1.6-3.2)	2.2 (1.5-3.2)	2.4 (1.1-5.0)	 	Gastric	Plain	2.0 (1.5-2.5)	2.0 (1.6-2.6)	- $	 		Coated	2.2 (1.4-3.6)	2.3 (1.4-3.8)		 	Duodenal	Plain	1.6 (1.3-2.1)	1.5 (1.2-2.0)	1.8 (1.1-2.8)	 		Coated	2.2 (1.4-3.4)	1.9 (1.1-3.2)	2.9# 	 	(1.4-6.1)	 	</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>17089</offset><text>* Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol $ Only 3 cases of 
gastric perforation exposed to plain aspirin and none to coated aspirin # Based 
on 9 exposed cases and 142 controls</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>17413</offset><text>Effect of aspirin formulation and dose on risk of UGIB and 
perforation among current users as compared to non-use</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot;&gt;&lt;bold&gt;Formulation/dose as instructed&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;Plain&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  ≤ 150 mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;201&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;626&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.6-2.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  300 + mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;30&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;69&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.6 (1.6-4.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;Enteric-coated&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  ≤ 150 mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;24&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;39&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3.5 (2.0-6.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  300 + mg&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;103&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.8 (1.2-2.8)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17528</offset><text>	All cases		 	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Formulation/dose as instructed	 	 Plain				 	  ≤ 150 mg	201	626	1.9 (1.6-2.2)	 	  300 + mg	30	69	2.6 (1.6-4.2)	 	 Enteric-coated				 	  ≤ 150 mg	24	39	3.5 (2.0-6.1)	 	  300 + mg	32	103	1.8 (1.2-2.8)	 	</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>17827</offset><text>* Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment 
for antiulcer drugs use did not change the estimates.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18093</offset><text>As shown in table 6, the duration of treatment had an  impact upon the risk of upper gastrointestinal complication, being the first  two months of use the period of greater risk (4.5, 2.9-7.1). Such a pattern was  observed across different doses (table 7) or formulations  of aspirin (see additional material: Appendix 3), though it was less sharp  within the 75 mg dose and for enteric-coated preparations. The indication for  aspirin in those patients with shorter treatment duration (less than 2 months)  was related to cardiovascular disorders in 88% of cases and 89 % of controls.  Among short-term users, those who used aspirin for the first time appeared to  be at the same relative risk as those with a previous non-consecutive  prescription of aspirin (&quot;distant use&quot;) (table 6). The  initial increased risk was clearly observed for bleeding lesions and less  markedly for perforation (see additional material: Appendix 4).</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19025</offset><text>Effect of duration of treatment with aspirin on the risk of UGIB 
and perforation among current users as compared to non-use</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Days of treatment&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(consecutive prescriptions)&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 1-60 (all users)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;52&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.5 (2.9-7.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  First-ever users&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;25&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.6 (2.7-8.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  Distant users&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;20&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.2 (2.0-8.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 61-180&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;34&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;71&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.7 (1.7-4.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; 181-730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;96&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;286&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (1.5-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &amp;gt;730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;117&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;428&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.6 (1.3-2.0)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19150</offset><text>	All cases		 	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Days of treatment				 	(consecutive prescriptions)				 	 1-60 (all users)	40	52	4.5 (2.9-7.1)	 	  First-ever users	25	32	4.6 (2.7-8.1)	 	  Distant users	15	20	4.2 (2.0-8.6)	 	 61-180	34	71	2.7 (1.7-4.2)	 	 181-730	96	286	1.9 (1.5-2.5)	 	 &gt;730	117	428	1.6 (1.3-2.0)	 	</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19507</offset><text>*Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment 
for antiulcer drugs use did not change the estimates.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19772</offset><text>The concomitant use of aspirin together with other non-aspirin NSAIDs at  high dose increased substantially the risk of major UGIC (relative risk 13.3,  8.5-20.9), far beyond the sum of their respective independent effects  (RERI=7.9, 2.0-13.8), while no interaction was apparent when low-dose aspirin  was taken together with NSAIDs at low-medium dose (RR of 2.2, 1.0-4.6) (table  8). The interaction appeared to be greater for  perforation (RR=30.3, 15.0-61.3; RERI=23.1, 2.2-44.2) than for bleeding  (RR=10.8, 6.6-17.5; RERI= 5.7, 0.5-10.9). Among bleeding lesions no difference  was found between the relative risk of the combination for those located at the  stomach (RR=12.2, 6.8-21.9) and those located at the duodenum (14.3, 8.3-24.5).  Both formulations of aspirin presented this interaction with high-dose NSAIDs  (plain, 12.7 (7.7-20.8); enteric-coated, 16.6 (5.9-46.3). No relevant  interaction beyond the sum of the independent effects was observed between  aspirin and high-dose paracetamol (4.5, 1.9-10.9) or aspirin and steroids (1.9,  0.9-3.8). A small interaction was observed between low-dose aspirin and  anticoagulants (5.5, 2.4-12.7).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>20929</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20940</offset><text>The results of the present study show that the use of low-dose aspirin for  prophylaxis of cardiovascular disorders conveys a twofold increased risk of  upper gastrointestinal bleeding and perforation in the general population. This  increased risk is found over different categories of age and sex. The effect of  aspirin applies equally to gastric and duodenal sites.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21310</offset><text>We did not find a clear relation with aspirin daily dose within the range  75-300 mg. Such a result did not change when we restricted the analysis to  patients without any antecedent of upper gastrointestinal disorder or when we  adjusted for use of antiulcer drugs. This reasonably excludes a potential  selection of patients with a greater risk of UGIC to lower doses of aspirin.  Looking for other sources of bias, we identified that in 13% of patients the  dose instructed by the general practitioner was not consistent with the average  daily dose calculated by counting the number of tablets supplied. We tried to  correct this by restricting the analysis to the population having consistent  data with both methods and by replacing the instructed dose by the average.  Neither of those corrections yielded different results. Nevertheless, a  suggestion of a greater risk associated with aspirin at higher doses within the  range 75-300 mg versus lower doses was found among users of the plain  formulation and among short-term users (first 60 days of treatment). Finally,  although the confidence intervals for lower doses are reasonably narrow, some  statistical uncertainty remains and a dose-effect cannot be excluded;  therefore, the use of the lowest dose shown effective is still the best  strategy to minimise risk.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22640</offset><text>The enteric-coated formulations appear not to protect from the  aspirin-induced risk of upper gastrointestinal bleeding, irrespective of the  dose, neither for gastric nor for duodenal lesions. This observation adds up to  previous results from other investigators. Assuming  that the coating of aspirin effectively spares the stomach from its topical  adverse effect, such results cast doubts on the overall contribution of the  local effect in serious bleeding lesions observed among aspirin users. Instead,  our findings support the hypothesis that the effect of aspirin, both plain and  enteric-coated, on upper gastrointestinal bleeding is mainly systemic mediated  through inhibition of platelet thromboxane A2 synthesis and/or inhibition of protective prostaglandin synthesis in  the gastroduodenal mucosa. A local effect, however,  cannot be ruled out as a relevant contributor for aspirin-induced perforation,  as most cases were located in duodenum, and no difference or, perhaps, a  slightly greater risk was found with the coated formulation. A preferential  prescription of enteric-coated aspirin to patients with antecedents of  gastrointestinal disorders does not explain our results, since enteric-coated  aspirin users with no such antecedents present a risk similar to the one  associated with plain aspirin.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23967</offset><text>Patients in the first two months after starting treatment with aspirin are  at the greatest risk of presenting a major UGIC. Thereafter, the risk goes down  and reaches a plateau at around six months. This phenomenon has been observed  by other researchers for aspirin but remains  controversial for other NSAIDs. It has been suggested that this high hazard rate at the beginning  of treatment could be an artefact induced by the use of aspirin for early  symptoms of peptic ulcer. This possibility can be reasonably ruled out in our  study because almost 90% of cases who experienced bleeding or perforation early  after starting treatment with aspirin were using it for prevention of  cardiovascular disorders, a pattern of use identical to the one found for new  users among controls. Another explanation argued for the decreasing risk with  the continuation of treatment has been the &quot;early withdrawal of population  susceptible to damage&quot;. In order to explore this  possibility we divided short-term users of aspirin (&lt; 2 months) into  &quot;distant users&quot; and &quot;first-ever users&quot;, depending on the recording or not of a  remote non-consecutive prescription for aspirin. We did not find any apparent  difference in risk between these two groups. So, patients who stopped treatment  with aspirin for whatever reason and then started again after a washout period  of at least four months, presented a similar risk during the first two months  of treatment as first-ever users. By exclusion, the duration response could be  explained by the third mechanism postulated so far: the existence of an  adaptation of the gastrointestinal mucosa to the toxic action of aspirin.  According to our results, this adaptation process would take at least 2 months  to result into clinical benefits. In striking contrast, a constant risk pattern  has been found with non-aspirin NSAIDs. The reasons for such discrepancy are unknown and should  be further studied. In our view, the explanation should be searched in the  pharmacological differences of aspirin as compared to non-aspirin NSAIDs. It is  well known that aspirin has a much greater topical adverse effect on the  stomach lining than non-aspirin NSAIDs and perhaps  the adaptive process concerns mainly this mechanism of action.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26239</offset><text>The concurrent use of low-dose aspirin with high-dose NSAIDs increases the  risk of UGIC by a factor of 13. Similar findings have been obtained by others  for UGIB. Our results strongly suggest that the  combination may have a particular impact on the risk of perforation (lower  confidence interval of 15). It is important to note that the joint use of  low-dose aspirin with high-dose NSAIDs is not unusual. In our random sample of  11,500 controls, the prevalence of this combination was 3 per 1,000 subjects, a  small figure in relative terms but large from a public health perspective. On  the other hand, it is reassuring that no interaction beyond the sum of their  respective effects was observed between aspirin and low-medium NSAIDs, aspirin  and steroids, or aspirin and paracetamol (even when this latter was taken at  doses higher than 2 grams a day). Although we detected a slight interaction of  low-dose aspirin and anticoagulants, the confidence interval of the estimate is  wide and precludes any firm conclusion.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27271</offset><text>The present study has some limitations. Aspirin prescription is  systematically recorded in the GPRD, but its over-the-counter use is only  recorded occasionally and this could lead to a misclassification of aspirin  exposure. Although misclassification of exposures collected prospectively  before the occurrence of the event of interest is usually close to  non-differential between cases and controls, we evaluated the extent of the  under-recording and the type of misclassification using external data from a  recent study that analyzed the risk of peptic ulcer bleeding associated with prophylactic aspirin and was also performed in the UK. The  authors interviewed patients aged 60 and over and asked, among other things,  information about all prescribed and self-administered drug intake. They found  that 27.1 % of cases and 15.9% of controls reported any use of aspirin in the  month before (16.5% and 8.3% respectively reported a regular use). In our study  population, the prevalence of aspirin use in the month before was 13.6% and  7.3% (18.4% and 10.3% among the subjects aged 60 years or older).  Interestingly, the case-control ratio of aspirin exposure for the reference  study is 1.70, while the corresponding ratio is 1.86 in our study (1.79 for the  older group). These figures suggest that the under-recording of OTC aspirin use  in our study is to a major extent non-differential with respect to case status.  We performed a sensitivity analysis assuming the worst case of a 50%  misclassification of aspirin users. The &quot;true&quot; crude OR would be 2.3 instead of  the 2.1 observed. Therefore, it seems unlikely that the underascertainment of  OTC aspirin use could have greatly distorted the estimate of aspirin effect in  our study. Other authors have recently reached the same conclusion for OTC  NSAIDs. It is conceivable that the potential  misclassification of enteric-coated preparations due to their higher price were  less important than for the plain ones. This means that the distortion to the  null would be weaker for the former preparations, but assuming that the  misclassification was non-differential with respect to case status, the impact  of such difference would be negligible. We also examined the effects of a  differential misclassification with respect to case status and only under the  unrealistic assumption of a strong differential misclassification selectively  affecting the higher doses within the range 75-300 mg of plain preparations,  could our results of lack of dose-effect and lack of protective effect of  enteric-coated preparations be explained.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29878</offset><text>We tried to control for other potential sources of bias, including  channelling of patients with greater risk to lower-dose or enteric-coated  aspirin. However, as with all observational studies, unmeasured or inaccurately  measured factors may lead to residual confounding.</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>30153</offset><text>Effect of duration of treatment with aspirin on the risk of UGIB 
and perforation among current users as compared to non-use by aspirin dose</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Daily dose as instructed/&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Days of treatment/&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;75 mg&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  1-60&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3.2 (1.7-6.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  61-180&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;20&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;37&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.9 (1.6-5.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  181-730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;53&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;166&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.7 (1.2-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  &amp;gt;731&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;51&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;185&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.7 (1.3-4.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;150 mg&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  1-60&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;11&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;6.6 (2.7-15.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  61-180&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;11&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.7 (1.2-6.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  181-730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;26&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;83&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.0 (1.2-3.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  &amp;gt;730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;34&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;128&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.5 (1.0-2.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; &lt;bold&gt;300 + mg&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  1-60&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;6.0 (2.2-16.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  61-180&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;11&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.9 (0.5-7.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  181-730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;37&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.6 (1.4-4.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;  &amp;gt;730&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;115&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1.7 (1.1-2.6)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>30294</offset><text>	All cases		 	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Daily dose as instructed/				 	Days of treatment/				 	 75 mg				 	  1-60	17	32	3.2 (1.7-6.1)	 	  61-180	20	37	2.9 (1.6-5.2)	 	  181-730	53	166	1.7 (1.2-2.5)	 	  &gt;731	51	185	1.7 (1.3-4.6)	 	 150 mg				 	  1-60	13	11	6.6 (2.7-15.9)	 	  61-180	11	23	2.7 (1.2-6.0)	 	  181-730	26	83	2.0 (1.2-3.2)	 	  &gt;730	34	128	1.5 (1.0-2.2)	 	 300 + mg				 	  1-60	10	9	6.0 (2.2-16.2)	 	  61-180	3	11	1.9 (0.5-7.1)	 	  181-730	17	37	2.6 (1.4-4.9)	 	  &gt;730	32	115	1.7 (1.1-2.6)	 	</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>30884</offset><text>*Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>31072</offset><text>Effect of concomitant use of aspirin and NSAIDs among current users 
as compared to non use of either drug (multiple users of NSAIDs were 
excluded).</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;All cases (UGIB/Perforation)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Controls&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adjusted RR&lt;sup&gt;*&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(N=2,105)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;
(N=11,500)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(95%CI)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Low-medium-dose NSAIDs only&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;
83(71/12)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;256&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.6 (2.0-3.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;High-dose&lt;sup&gt;#&lt;/sup&gt; NSAIDs only&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;254 
(202/52)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;413&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.3 (3.6-5.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Only aspirin&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;221 (201/20)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;767&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.1 (1.8-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Aspirin + low-medium-dose NSAIDs&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;9 
(6/3)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;34&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2.2 (1.0-4.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Aspirin + high-dose&lt;sup&gt;#&lt;/sup&gt; NSAIDs&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;57 (41/16)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;36&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;13.3 
(8.5-20.9)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>31222</offset><text>	All cases (UGIB/Perforation)	Controls	Adjusted RR*	 		(N=2,105)		 	(N=11,500)	(95%CI)	 	Low-medium-dose NSAIDs only		 	83(71/12)	256	2.6 (2.0-3.4)	 	High-dose# NSAIDs only	254 	 	(202/52)	413	4.3 (3.6-5.2)	 	Only aspirin	221 (201/20)	767	2.1 (1.8-2.5)	 	Aspirin + low-medium-dose NSAIDs	9 	 	(6/3)	34	2.2 (1.0-4.6)	 	Aspirin + high-dose# NSAIDs	57 (41/16)	36	13.3 	 	(8.5-20.9)	 	</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>31604</offset><text>*Adjusted for sex, age, calendar year, antecedents of 
gastrointestinal disorders, smoking status, alcohol consumption and use of 
anticoagulants, steroids, SSRIs and paracetamol. # High-dose NSAIDs: 
Aceclofenac &gt; 100, acemetacin &gt; 120, diclofenac &gt; 75, etodolac 
&gt; 400, fenbufen &gt; 900, fenoprofen &gt; 1200, flurbiprofen &gt; 150, 
ibuprofen &gt; 1200, indometacin &gt; 75, ketoprofen &gt; 100, mefenamic 
acid &gt; 1000, tiaprofenic acid &gt; 450, azapropazone &gt; 600, meloxicam 
&gt; 7.5, nabumetone &gt; 1000, naproxen &gt; 500, piroxicam &gt; 10, 
sulindac &gt; 200, tenoxicam &gt; 10 (all doses in mg).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>32174</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>32186</offset><text>Aspirin used at doses as low as 75 mg is still associated with a moderate  risk of developing serious upper gastrointestinal complications. The coating of  the active principle in order to spare the stomach does not reduce the risk of  upper gastrointestinal complications, neither for the stomach nor for the  duodenum. The first two months of treatment seem to be the period of greater  risk, regardless the patient is first-ever user or not. Patients using  concomitantly low-dose aspirin and high-dose nonaspirin NSAIDs are a subgroup  of patients with a major increased risk of upper gastrointestinal  complications.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title_1</infon><offset>32808</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>32822</offset><text>UGIB: Upper gastrointestinal bleeding; UGIC: Upper gastrointestinal  complications; NSAIDs: Non-steroidal and anti-inflammatory drugs; RR; Relative  risk; GPRD: General Practice Research Database.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>33019</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>33043</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>33108</offset><text>Supplementary Material</text></passage><passage><infon key="fpage">1287</infon><infon key="lpage">1294</infon><infon key="name_0">surname:Patrono;given-names:C</infon><infon key="pub-id_pmid">8145785</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">330</infon><infon key="year">1994</infon><offset>33131</offset><text>Aspirin as an antiplatelet drug.</text></passage><passage><infon key="fpage">1563</infon><infon key="lpage">1566</infon><infon key="name_0">surname:Henry;given-names:D</infon><infon key="name_1">surname:Lim;given-names:LLY</infon><infon key="name_10">surname:Hill;given-names:S</infon><infon key="name_11">surname:Fries;given-names:JT</infon><infon key="name_2">surname:García Rodríguez;given-names:LA</infon><infon key="name_3">surname:Pérez Gutthann;given-names:S</infon><infon key="name_4">surname:Carson;given-names:JL</infon><infon key="name_5">surname:Griffin;given-names:M</infon><infon key="name_6">surname:Savage;given-names:R</infon><infon key="name_7">surname:Logan;given-names:R</infon><infon key="name_8">surname:Moride;given-names:Y</infon><infon key="name_9">surname:Hawkey;given-names:C</infon><infon key="pub-id_pmid">8664664</infon><infon key="section_type">REF</infon><infon key="source">Br Med J</infon><infon key="type">ref</infon><infon key="volume">312</infon><infon key="year">1996</infon><offset>33164</offset><text>Variability in risk of gastrointestinal complications with individual  NSAIDs. results of a collaborative meta-analysis.</text></passage><passage><infon key="fpage">827</infon><infon key="lpage">830</infon><infon key="name_0">surname:Weil;given-names:J</infon><infon key="name_1">surname:Colin-Jones;given-names:D</infon><infon key="name_2">surname:Langman;given-names:M</infon><infon key="name_3">surname:Lawson;given-names:D</infon><infon key="name_4">surname:Logan;given-names:R</infon><infon key="name_5">surname:Murphy;given-names:M</infon><infon key="name_6">surname:Rawlins;given-names:M</infon><infon key="name_7">surname:Vessey;given-names:M</infon><infon key="name_8">surname:Wainwright;given-names:P</infon><infon key="pub-id_pmid">7711618</infon><infon key="section_type">REF</infon><infon key="source">Br Med J</infon><infon key="type">ref</infon><infon key="volume">310</infon><infon key="year">1995</infon><offset>33285</offset><text>Prophylactic aspirin and risk of peptic ulcer bleeding.</text></passage><passage><infon key="fpage">1413</infon><infon key="lpage">1416</infon><infon key="name_0">surname:Kelly;given-names:JP</infon><infon key="name_1">surname:Kaufman;given-names:DW</infon><infon key="name_2">surname:Jurgelon;given-names:JM</infon><infon key="name_3">surname:Sheehan;given-names:J</infon><infon key="name_4">surname:Koff;given-names:RS</infon><infon key="name_5">surname:Shapiro;given-names:S</infon><infon key="pub-id_pmid">8937281</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">348</infon><infon key="year">1996</infon><offset>33341</offset><text>Risk of aspirin-associated major upper-gastrointestinal bleeding with  enteric-coated or buffered product.</text></passage><passage><infon key="name_0">surname:Rowland;given-names:M</infon><infon key="name_1">surname:Tozer;given-names:TN</infon><infon key="section_type">REF</infon><infon key="source">Lea &amp; Febiger, Philadelphia:</infon><infon key="type">ref</infon><infon key="year">1980</infon><offset>33448</offset><text>Clinical pharmacokinetics- concepts and applications.</text></passage><passage><infon key="fpage">390</infon><infon key="lpage">398</infon><infon key="name_0">surname:Graham;given-names:DY</infon><infon key="name_1">surname:Smith;given-names:JL</infon><infon key="pub-id_pmid">3511824</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">104</infon><infon key="year">1986</infon><offset>33502</offset><text>Aspirin and the stomach.</text></passage><passage><infon key="fpage">609</infon><infon key="lpage">612</infon><infon key="name_0">surname:Hoftiezer;given-names:JW</infon><infon key="name_1">surname:Silvoso;given-names:GR</infon><infon key="name_2">surname:Burks;given-names:M</infon><infon key="name_3">surname:Ivey;given-names:KJ</infon><infon key="pub-id_pmid">6107406</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1980</infon><offset>33527</offset><text>Comparison of the effects of regular and enteric-coated aspirin on  gastroduodenal mucosa of man.</text></passage><passage><infon key="fpage">136</infon><infon key="lpage">138</infon><infon key="name_0">surname:Lanza;given-names:FL</infon><infon key="name_1">surname:Royer;given-names:GL;suffix:Jr</infon><infon key="name_2">surname:Nelson;given-names:RS</infon><infon key="pub-id_pmid">6966762</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">303</infon><infon key="year">1980</infon><offset>33625</offset><text>Endoscopic evaluation of the effects of aspirin, buffered aspirin,  and enteric-coated aspirin on gastric and duodenal mucosa.</text></passage><passage><infon key="fpage">77</infon><infon key="lpage">83</infon><infon key="name_0">surname:Hawthorne;given-names:AB</infon><infon key="name_1">surname:Mahida;given-names:YR</infon><infon key="name_2">surname:Cole;given-names:AT</infon><infon key="name_3">surname:Hawkey;given-names:CJ</infon><infon key="pub-id_pmid">1888645</infon><infon key="section_type">REF</infon><infon key="source">Br J Clin Pharmacol</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">1991</infon><offset>33752</offset><text>Aspirin-induced gastric mucosa damage: prevention by enteric-coating  and relation to prostaglandin synthesis.</text></passage><passage><infon key="name_0">surname:García Rodríguez;given-names:LA</infon><infon key="name_1">surname:Hernández;given-names:S</infon><infon key="section_type">REF</infon><infon key="source">Epidemiology</infon><infon key="type">ref</infon><offset>33863</offset><text>The risk of upper gastrointestinal complications among users of  paracetamol and other non-steroidal antiinflammatory drugs.</text></passage><passage><infon key="fpage">419</infon><infon key="lpage">425</infon><infon key="name_0">surname:García Rodríguez;given-names:LA</infon><infon key="name_1">surname:Pérez Gutthann;given-names:S</infon><infon key="pub-id_pmid">9643612</infon><infon key="section_type">REF</infon><infon key="source">Br J Clin Pharmacol</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1998</infon><offset>33988</offset><text>Use of the UK General Practice Research Database for  pharmacoepidemiology.</text></passage><passage><infon key="fpage">766</infon><infon key="lpage">768</infon><infon key="name_0">surname:Jick;given-names:H</infon><infon key="name_1">surname:Jick;given-names:SS</infon><infon key="name_2">surname:Derby;given-names:LE</infon><infon key="pub-id_pmid">2021768</infon><infon key="section_type">REF</infon><infon key="source">Br Med J</infon><infon key="type">ref</infon><infon key="volume">302</infon><infon key="year">1991</infon><offset>34064</offset><text>Validation of information recorded on general practitioner based  computerised data resource in the United Kingdom.</text></passage><passage><infon key="fpage">769</infon><infon key="lpage">772</infon><infon key="name_0">surname:García Rodríguez;given-names:LA</infon><infon key="name_1">surname:Jick;given-names:H</infon><infon key="pub-id_pmid">7907735</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">343</infon><infon key="year">1994</infon><offset>34180</offset><text>Risk of upper gastrointestinal bleeding and perforation associated  with individual nonsteroidal anti-inflammatory drugs.</text></passage><passage><infon key="fpage">75</infon><infon key="lpage">80</infon><infon key="name_0">surname:Walker;given-names:AM</infon><infon key="section_type">REF</infon><infon key="source">Walker AM. Observation and Inference: An introduction to the 
methods of epidemiology. Chestnut Hill, MA: Epidemiology Resources 
Inc.,</infon><infon key="type">ref</infon><infon key="year">1991</infon><offset>34302</offset><text>Case-control studies: sampling the source population.</text></passage><passage><infon key="fpage">18</infon><infon key="lpage">24</infon><infon key="name_0">surname:Pérez Gutthann;given-names:S</infon><infon key="name_1">surname:García Rodríguez;given-names:LA</infon><infon key="name_2">surname:Raiford;given-names:DS</infon><infon key="pub-id_pmid">9116088</infon><infon key="section_type">REF</infon><infon key="source">Epidemiology</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1997</infon><offset>34356</offset><text>Individual non-steroidal anti-inflammatory drugs and hospitalizations  for upper gastrointestinal bleeding and perforation.</text></passage><passage><infon key="fpage">1106</infon><infon key="lpage">1109</infon><infon key="name_0">surname:De Abajo;given-names:FJ</infon><infon key="name_1">surname:García Rodríguez;given-names:LA</infon><infon key="name_2">surname:Montero;given-names:D</infon><infon key="pub-id_pmid">10531103</infon><infon key="section_type">REF</infon><infon key="source">Br Med J</infon><infon key="type">ref</infon><infon key="volume">319</infon><infon key="year">1999</infon><offset>34480</offset><text>Association between selective serotonin reuptake inhibitors and upper  gastrointestinal bleeding: a population based case-control study.</text></passage><passage><infon key="name_0">surname:Rothman;given-names:KJ</infon><infon key="section_type">REF</infon><infon key="source">Modern Epidemiology, 1st ed, Little, Brown and Company, Boston:</infon><infon key="type">ref</infon><infon key="year">1986</infon><offset>34617</offset></passage><passage><infon key="fpage">452</infon><infon key="lpage">456</infon><infon key="name_0">surname:Hosmer;given-names:DW</infon><infon key="name_1">surname:Lemeshow;given-names:S</infon><infon key="pub-id_pmid">1391139</infon><infon key="section_type">REF</infon><infon key="source">Epidemiology</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">1992</infon><offset>34618</offset><text>Confidence interval estimation of interaction.</text></passage><passage><infon key="fpage">9</infon><infon key="lpage">13</infon><infon key="name_0">surname:Ali;given-names:M</infon><infon key="name_1">surname:McDonald;given-names:JW</infon><infon key="name_2">surname:Thiessen;given-names:JJ</infon><infon key="name_3">surname:Coates;given-names:PE</infon><infon key="pub-id_pmid">7355437</infon><infon key="section_type">REF</infon><infon key="source">Stroke</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1980</infon><offset>34665</offset><text>Plasma acetylsalicylate and salicylate and platelet cyclo-oxygenase  activity following plain and enteric-coated aspirin.</text></passage><passage><infon key="fpage">1888</infon><infon key="lpage">1899</infon><infon key="name_0">surname:Wolfe;given-names:MM</infon><infon key="name_1">surname:Lichtenstein;given-names:DR</infon><infon key="name_2">surname:Singh;given-names:G</infon><infon key="pub-id_pmid">10369853</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">340</infon><infon key="year">1999</infon><offset>34787</offset><text>Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.</text></passage><passage><infon key="fpage">24</infon><infon key="lpage">31</infon><infon key="name_0">surname:Lanza;given-names:FL</infon><infon key="pub-id_pmid">2683026</infon><infon key="section_type">REF</infon><infon key="source">Scand J Gastroenterol Suppl</infon><infon key="type">ref</infon><infon key="volume">163</infon><infon key="year">1989</infon><offset>34853</offset><text>A review of gastric ulcer and gastroduodenal injury in normal  volunteers receiving aspirin and other non-steroidal anti-inflammatory  drugs.</text></passage><passage><infon key="fpage">S37</infon><infon key="name_0">surname:Yood;given-names:MU</infon><infon key="name_1">surname:Rothman;given-names:KJ</infon><infon key="name_2">surname:Johnson;given-names:CC</infon><infon key="name_3">surname:Jick;given-names:S</infon><infon key="name_4">surname:Lang;given-names:J</infon><infon key="name_5">surname:Wells;given-names:KE</infon><infon key="name_6">surname:Jick;given-names:H</infon><infon key="section_type">REF</infon><infon key="source">Pharmacoepidemiology and Drug Safety</infon><infon key="type">ref</infon><infon key="volume">9 (suppl 1)</infon><infon key="year">2000</infon><offset>34995</offset><text>Using prescription claims data for drugs available over-the-counter  (OTC).</text></passage></document></collection>
